( MINNEAPOLIS May 23 2007 (BUSINESS WI...)Aquavan (Fospropofol Disodium) Injection Data Presented at,Digestive Disease Week 2007,Health

MINNEAPOLIS, May 23, 2007 (BUSINESS WIRE) -- MGI PHARMA, INC. (NASDAQ:MOGN), a biopharmaceutical company focused in oncology and acute care, today announced the presentation of results of a successful pivotal phase 3 trial of Aquavan(R) (fospropofol disodium) Injection in patients undergoing colonoscopy. Primary and secondary efficacy endpoint results, as well as safety data, were presented at Digestive Disease Week 2007 in Washington, D.C. by Lawrence B. Cohen, MD, Department of Medicine/ Gastroenterology, Mount Sinai School of Medicine, New York.

Aquavan Injection is a proprietary water-soluble prodrug of propofol that is in clinical development for moderate sedation of patients undergoing therapeutic and diagnostic procedures. Aquavan has not yet been approved for marketing by the U.S. Food and Drug Administration (U.S. FDA) or any other regulatory agencies.

"Aquavan has a favorable pharmacokinetic profile, making it possible to deliver a predictable concentration of sedative and achieve the desired level of sedation," said Dr. Cohen, a lead investigator of the trial.

Colonoscopy Results: Primary Endpoint of Sedation Success Achieved (Abstract W1451)

A randomized, double-blind, multi-center phase 3 pivotal trial was conducted to evaluate whether an Aquavan dosing regimen of 6.5 mg/kg would be safe and effective in providing moderate sedation in patients undergoing colonoscopy, compared to a 2.0 mg/kg Aquavan regimen. A total of 312 patients in 18 sites were pre-treated with fentanyl citrate (50 (mu)g) and then received either Aquavan 2.0 mg/kg, Aquavan 6.5 mg/kg or midazolam 0.02 mg/kg (2:3:1 ratio). Gastroenterologists administered the sedatives, as is consistent with a large percentage of routine colonoscopies. Patients were ages 18 and older and in varying states of health and sedation risk.

The results showed that 87% of patients who received an initial bolus dose
'"/>